Two new non-nucleoside reverse transcriptase inhibitors (NNRTIs) have demonstrated good antiviral efficacy and favourable safety profiles in seven-day monotherapy trials, according to late-breaker presentations at the XVII International AIDS Conference in Mexico City.
http://www.aidsmap.org/en/news/18A8C416-4BD7-4060-A556-46EAB9271E04.asp